InflaRx (IFRX) Net Equity Issued and Repurchased (2016 - 2025)

InflaRx (IFRX) posted Net Equity Issued and Repurchased of $7.9 million for Q4 2025, down 53.68% sequentially from $17.0 million in Q1 2025.

InflaRx (IFRX) Net Equity Issued and Repurchased (2016 - 2025) Analysis & Trends

InflaRx has reported Net Equity Issued and Repurchased for 5 years, with the latest figure at $7.9 million in Q4 2025.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $7.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.8 million (changed N/A YoY) and the FY2025 annual result came in at $25.9 million, up 2076.6% from the prior year.
Net Equity Issued and Repurchased fell to $7.9 million in Q4 2025 per IFRX's latest filing, from $17.0 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $78.6 million in Q1 2021 and troughed at $7.9 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	InflaRx	140.30 Mn	-43.96 Mn	2.74 Bn	-

Download Data